STO-609
目录号 : GC37694
STO-609是一种选择性且细胞可渗透的Ca²⁺/钙调蛋白依赖性蛋白激酶激酶（CaM-KK）抑制剂，对重组CaM-KKα和CaM-KKβ的Ki值分别为80ng/mL和15ng/mL。
Cas No.:52029-86-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
STO-609 is a selective and cell-permeable inhibitor of the Ca2+/calmodulin-dependent protein kinase kinase (CaM-KK), with Ki values of 80 and 15ng/mL for recombinant CaM-KKα and CaM-KKβ, respectively[1]. CaM-KK is a key signal transduction protein that plays an important role in intracellular calcium signal transduction by activating members of the CaM kinase family (such as CaM-KI, CaM-KIV, etc.)[2]. STO-609 is typically used to study CAM-KK-related signaling pathways and their roles in various cellular physiological processes such as cell proliferation, differentiation, metabolism, and neural signal transduction[3][4].
In vitro, treatment of non-functional pituitary adenoma (NFPA) cells with STO-609 (0.4-51.2μM; 24h)significantly inhibits cells proliferation and migration and induces apoptosis in a dose-dependent manner by suppressing the Ca²⁺/CaM signaling pathway[5]. Treatment of insect neurosecretory cells with STO-609 (15μM; 10min) significantly reduced nicotine-induced currents and intracellular calcium levels increase by inhibiting the CaMKK/AMPK pathway[6].
In vivo, STO-609 (30μg/kg; i.p.; twice a week; 3 weeks) significantly reduced the lung weight of mice inhibited experimental lung metastasis in mice with oral squamous cell carcinoma (OSCC) cells overexpressing EP4[7].
References:
[1] Tokumitsu H, Inuzuka H, Ishikawa Y, Ikeda M, Saji I, Kobayashi R. STO-609, a specific inhibitor of the Ca(2+)/calmodulin-dependent protein kinase kinase. J Biol Chem. 2002;277(18):15813-15818.
[2] Tokumitsu H, Sakagami H. Molecular Mechanisms Underlying Ca2+/Calmodulin-Dependent Protein Kinase Kinase Signal Transduction. Int J Mol Sci. 2022;23(19):11025.
[3] York B, Li F, Lin F, et al. Pharmacological inhibition of CaMKK2 with the selective antagonist STO-609 regresses NAFLD. Sci Rep. 2017;7(1):11793.
[4] Fujiwara Y, Hiraoka Y, Fujimoto T, Kanayama N, Magari M, Tokumitsu H. Analysis of Distinct Roles of CaMKK Isoforms Using STO-609-Resistant Mutants in Living Cells. Biochemistry. 2015;54(25):3969-3977.
[5] Wu B, Jiang S, Wang X, et al. Identification of driver genes and key pathways of non-functional pituitary adenomas predicts the therapeutic effect of STO-609. PLoS One. 2020;15(10):e0240230.
[6] Taha M, Houchat JN, Taillebois E, Thany SH. The calcium-calmodulin-dependent protein kinase kinase inhibitor, STO-609, inhibits nicotine-induced currents and intracellular calcium increase in insect neurosecretory cells. J Neurochem. 2024;168(7):1281-1296.
[7] Ishikawa S, Umemura M, Nakakaji R, et al. EP4-induced mitochondrial localization and cell migration mediated by CALML6 in human oral squamous cell carcinoma. Commun Biol. 2024;7(1):567.
STO-609是一种选择性且细胞可渗透的Ca²⁺/钙调蛋白依赖性蛋白激酶激酶（CaM-KK）抑制剂，对重组CaM-KKα和CaM-KKβ的Ki值分别为80ng/mL和15ng/mL[1]。CaM-KK是一种关键的信号转导蛋白，通过激活CaM激酶家族成员（如CaM-KI、CaM-KIV等）在细胞内钙信号传导中发挥重要作用[2]。STO-609通常用于研究CaM-KK相关的信号通路及其在细胞增殖、分化、代谢和神经信号传导等多种细胞生理过程中的作用[3][4]。
在体外，STO-609（0.4-51.2μM；处理24小时）通过抑制Ca2+/CaM信号通路, 剂量依赖性地显著抑制非功能性垂体腺瘤（NFPA）细胞的增殖和迁移，并诱导细胞凋亡[5]。在昆虫的神经分泌细胞中，STO-609（15μM；处理10分钟）通过抑制CaMKK/AMPK通路显著降低了尼古丁诱导的电流和细胞内钙水平的升高[6]。
在体内，STO-609（30μg/kg；腹腔注射；每周两次；持续3周）显著降低了过表达EP4的口腔鳞状细胞癌（OSCC）细胞诱导的小鼠的肺重量，并抑制了小鼠实验性肺转移[7]。
| Cell experiment [1]: | |
Cell lines | HP75 cells |
Preparation Method | HP75 cells were cultured in DMEM containing 15% horse serum, and 2.5% fetal calf serum at 37˚C in an easeful air atmosphere containing 5% carbon dioxide. The cells were seeded into 96-well plates for overnight, and the density is 1.0×105 cells/well. After washing culture medium, different doses of STO-609 were used to the cells and cultured for 24h, control group and solvent control group were classed by using normal saline (NS) and DMSO respectively, and 6 wells were prepared for doses of STO-609 (concentration gradients were 0.4μmol/L, 0.8μmol/L, 1.6μmol/L, 3.2μmol/L, 6.4μmol/L, 12.8μmol/L, 25.6μmol/L and 51.2μmol/L). Cells were cultured for 1h after added CCK-8 into wells with a quantity of 10μl/well. The wave length of 450nm was applied to measure OD value of each well on the microplate reader. |
Reaction Conditions | 0.4-51.2μM; 24h |
Applications | STO-609 significantly inhibits cells proliferation and migration and induces apoptosis in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | BALB/c Slc-nu/nu mice |
Preparation Method | HSC-3 cells transfected with the lentiviral scramble control or EP4 over expression were harvested and injected (2×106cells/0.2mL) into the tail veins of BALB/c Slc-nu/nu mice (female, 4–5 weeks old, 4 mice/group) (SLC). Each group of mice was administered either vehicle (0.1% dimethylsulfoxide in phosphate-buffered saline) or STO-609 by intraperitoneal injection (30μg/kg/body weight) twice per week for 3 weeks. Three weeks after the injection of the cells, the lungs were fixed with formalin, and the weights were measured. |
Dosage form | 30μg/kg; i.p.; twice per week; 3 weeks |
Applications | STO-609 significantly reduced the lung weight of mice. |
References: | |
| Cas No. | 52029-86-4 | SDF | |
| Canonical SMILES | O=C(C1=C2C3=C(C4=NC5=CC=CC=C5N4C(C3=CC=C2)=O)C=C1)O | ||
| 分子式 | C19H10N2O3 | 分子量 | 314.29 |
| 溶解度 | DMSO: 5.6 mg/mL (17.82 mM and warming); Water: < 0.1 mg/mL (insoluble) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.1818 mL | 15.9089 mL | 31.8177 mL |
| 5 mM | 0.6364 mL | 3.1818 mL | 6.3635 mL |
| 10 mM | 0.3182 mL | 1.5909 mL | 3.1818 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet